Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Secondary endpoints: details revised at 2 of 3 entries
    • Site details revised at 4 of 4 sites
    • Collaborators: 3 to 4
    • Eligibility criteria expanded, about 4 words
  2. Primary endpoints revised (2)v2 Show 5 more changesShow less
    • Start date: Jan 2, 2026 to Jan 15, 2026
    • Eligibility criteria revised
    • Secondary endpoints revised (3)
    • Study description shortened, about 39 words
    • Study title expanded, about 1 word
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging. The aim is to reduce reliance on invasive procedures, shorten diagnostic timelines, and enhance accessibility to definitive diagnosis and treatment globally.
Trial Details
NCT Number NCT07297745
Lead Sponsor Changi General Hospital
Collaborators: Singapore General Hospital, Sengkang General Hospital, National University Hospital, Singapore, Khoo Teck Puat Hospital
Conditions
(from sponsor)		 Hyperaldosteronism; Primary, Primary Aldosteronism Due to Aldosterone Producing Adenoma
Related terms Hyperaldosteronism
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov